Raptis D, Schneider IHF, Matzel KE, Ott O, Fietkau R, Hohenberger W (2015)
Publication Type: Journal article
Publication year: 2015
Book Volume: 112
Pages Range: 243-9
Journal Issue: 14
DOI: 10.3238/arztebl.2015.0243
Anal carcinoma accounts for 2-4% of all cases of colorectal and anorectal carcinoma. Its peak incidence is from age 58 to age 64; women are affected somewhat more commonly than men. Its incidence has risen markedly in the past three decades.This article is based on a selective review of the literature, including the guidelines of the National Comprehensive Cancer Network and the European Society of Medical Oncology.Anal carcinoma is often an incidental finding. About 85% of newly diagnosed cases are associated with an HPV infection with strain 16, 18, or 33. Radiochemotherapy with 5-fluorouracil and mitomycin C is the treatment of choice. The 5-year survival rate is 80-90%. Primary surgery with curative intent is indicated only for well-differentiated carcinoma of the anal margin (T1, N0). 10-30% of patients now undergo radical resection. The utility of endosonography and positron emission tomography for staging is debated and needs further study.The treatment of patients with anal carcinoma requires a specialized multidisciplinary approach in accordance with the current evidence-based guidelines. The potential role of prophylactic vaccination against oncogenic types of HPV in the prevention of anal carcinoma merits further investigation.
APA:
Raptis, D., Schneider, I.H.F., Matzel, K.E., Ott, O., Fietkau, R., & Hohenberger, W. (2015). The Differential Diagnosis and Inter - disciplinary Treatment of Anal Carcinoma. Deutsches Ärzteblatt international, 112(14), 243-9. https://doi.org/10.3238/arztebl.2015.0243
MLA:
Raptis, Dimitrios, et al. "The Differential Diagnosis and Inter - disciplinary Treatment of Anal Carcinoma." Deutsches Ärzteblatt international 112.14 (2015): 243-9.
BibTeX: Download